Penumbra Inc. (PEN)
Penumbra Inc. (PEN) Stock Price, Analysis & Data
Keine Daten verfügbar
| Geld | n/a |
| Marktkapitalisierung | 12.89 Mrd |
| Umsatz (TTM) | 1.5 Mrd |
| Nettogewinn (TTM) | 160.59 Mio |
| Beta | 0.70 |
| EPS (ttm) | 4.06 |
| KGV (TTM) | 80.58 |
| Forward-KGV | 53.36 |
| KBV (TTM) | 8.42 |
| KUV (TTM) | 8.56 |
| Earnings Date | Nov 4, 2026 |
| Brief | n/a |
| Volumen | 154,029 |
| Ø Vol. (20D) | 388,270 |
| Eröffnung | 326.36 |
| Vortagesschluss | 327.02 |
| Tagesspanne | 326.51 - 327.61 |
| 52-Wk Range | 221.26 - 362.41 |
| Analyst | n/a |
| Kursziel | n/a |
| Dividenden | n/a |
| Ex-Dividenden-Datum | n/a |
Über PEN
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access prod...
Finanzielle Entwicklung
Im Jahr 2025 betrug der Umsatz von Penumbra 1.4 Mrd, ein Anstieg von 17.5% im Vergleich zum Vorjahr (1.19 Mrd). Der Gewinn lag bei 177.69 Mio, ein Anstieg von 1,168.11 %.
FinanzberichteGewinnüberraschung
Analysten erwarten einen Umsatz von ... Upgrade
vor 3 Wochen · Simply Wall St.
Penumbra (PEN) Wins FDA Clearance For THUNDERBOLT After Strong Stroke StudyPenumbra (NYSE:PEN) received FDA clearance for its THUNDERBOLT computer-assisted vacuum thrombectomy system for acute ischemic stroke treatment. The THUNDER study reported strong safety and efficacy r...